|
Sign In to gain access to subscriptions and/or personal tools.
|
The rasH2 Transgenic Mouse: Nature of the Model and Mechanistic Studies on Tumorigenesis
Norikazu Tamaoki
Tokai University School of Medicine, Central Institute for Experimental Animals, 1430 Nogawa, Miyamae, Kawasaki, 216-0001, Japan
The rasH2 mouse is a hemizygous transgenic mouse carrying the c-Ha-ras oncogene and that gene's promotor/enhancer within the genetic background of a BALB/cByJ C57BL/6J F1 mouse. Approximately 3 copies of the transgene are integrated in a tandem array into chromosome number 15. The transgene is transmitted stably without point mutation in hot spots and is expressed in all tissues over 20 backcross generations. The homozygous c-Ha-ras genotype is lethal. Hemizygotes are selected by polymerase chain reaction (PCR) analysis of tail tips after birth. Spontaneous tumors in hemizygous transgenic mice are rare until 6 months of age. The observed rasH2 tumor spectrum, including lung adenoma/adenocarcinoma, forestomach and skin papillomas, Harderian gland adenoma, liver proliferative lesions, splenic hemangioma/sarcoma, and lymphoma is consistent with the BALB/c and C57BL/6 background. In the rasH2 mouse, point mutations of the transgene induced by genotoxins are reported frequently but not in all tumors. Elevated levels of transgene expression were detected in all genotoxin-induced tumors in the rasH2. Increased transgene expression was independent of the mutation rate in transgenic and endogenous ras genes. These observations suggest that the overexpression of transgenic c-Ha-ras is responsible for accelerated tumor development.
Key Words: Carcinogenesis • carcinogenicity testing • c-Ha-ras • oncogene expression • oncogene mutation • ras oncogene • transgenic mouse.
References
- Ando K., Saitoh A., Hino O., Takahashi R., Kimura M., Katsuki M. (1992). Chemically induced forestomach papillomas in transgenic mice carry mutant human c-Ha-ras transgenes. Cancer Res 52: 978—982.[Abstract/Free Full Text]
- Ariyoshi T. (2001). The rasH2 Transgenic Mouse: Nature of the Model and Mechanistic Study on Tumorigenesis. Toxicol Pathol 29(Suppl.): xx—xx.
- Barbacid M. (1987). ras genes. Ann Rev Biochem 56: 779—827.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Bos LJ (1989). Ras oncogenes in human cancer: A review. Cancer Res 49: 4682—4689.[Abstract/Free Full Text]
- Chang EH, Furth ME, Scolnick EM, Lowy DR ( 1982). Tumorigenic transformation of mammalian cells induced by a normal human genehomologous to the oncogene of Harvey murine sarcoma virus. Nature 297: 479—483.[CrossRef][Medline]
[Order article via Infotrieve]
- Chin L., Tam A., Pomerantz J., Wong M., Holash J., Bardeesy N., Shen Q., O'HaganR., Pantginis J., Zhou H., Horner JW, Cordon-Cardo C., Yancopoulos G., Depinho R. (1999). Essential role for oncogene Ras in tumour maintenance. Nature 400: 468—472.[CrossRef][Medline]
[Order article via Infotrieve]
- Cohen JB, Levinson AD (1988). A point mutation in the last intron responsible for increased expression and transforming activity of the c-Ha-ras oncogene. Nature 334: 119—124.[CrossRef][Medline]
[Order article via Infotrieve]
- Doi S., Kimura M., Katsuki M. (1994). Site-specifi c mutation of the human c-Ha-ras transgene induced by dimethylbenzanthracene causes tissuespecifi c tumors in mice. Jpn J Cancer Res 85: 801—807.[CrossRef][Web of Science]
- Engelbergs J., Thomale J., Rajewsky MF (2000). Role of DNA repair in carcinogen-induced ras mutation. Mutat Res 450: 139—153.[Web of Science][Medline]
[Order article via Infotrieve]
- Hayashi S., Mori I., Nonoyama T., Mitsumori K. (1998). Point mutaions of the c-Ha-ras gene in spontaneous liver tumors of transgenic mice carrying the human c-Ha-ras Gene. Toxicol Pathol 26: 556— 561.
- Inoue R., Ushijima T., Katami M., Kushida H., Wakabayashi K., Sato H., Asamoto M., Katsuki M., Sugimura T., Nagao M. (1996). Rare activation of the human c-Ha-ras transgene of mice in hemangiendothelial sarcomas and liver tumors induced by Glu-P-1. Jpn J Cancer Res 87: 583—588.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Maruyama C., Yamazaki H., Tomisawa M., Urano K., Hioki K., Suemizu H., Wakana S., Ohnishi Y., Kijima H., Nakamura M., Ueyama Y., Tsuchida T., Mitsumori K., Nomura T., Tamaoki N. (2001). Overexpression of human H-ras transgene in tumors of rasH2 mice inducede by ethyl- and methylnitrosourea. Toxicol Pathol 29(Suppl.): xx—xx.
- Maruyama C., Tomisawa M., Wakana S., Yamazaki H., Suemizu H., Ohnishi Y., Uranao K., Hioki K., Usui T., Nakamura M., Tsuchida T., Mitsumori K., Nomura T., Tamaoki N., Ueyama Y. (2001). Overexpression of human H-ras transgene is responsible for tumors induced by chemical carcinogens in mice. Oncol Reports 8: 233—237.[Web of Science][Medline]
[Order article via Infotrieve]
- Mitsumori K., Wakana S., Yamamoto S., Kodama Y., Yasuhara K., Nomura T., Hayashi Y., MaronpotRR (1997). Susceptibilityoftransgenicmicecarrying human prototype c-Ha-ras gene in a short-term carcinogenicity study of vinyl carbamate and ras gene analyses of the induced tumors. Mol Carcinog 20: 298—307.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Mitsumori K., Koizumi H., Nomura T., Yamamoto S. (1998). Pathological features of spontanenous and induced tumors in transgenic mice carrying a human prototype c-Ha-ras gene used for six-month carcinogenesis studies. Toxicol Pathol 26: 520—531.[Abstract/Free Full Text]
- Nomura T, Esaki K, Tomita T (eds) (1980 ). ICLAS Manual for Genetic Monitoring of Inbred Mice. University of Tokyo Press, Tokyo, Japan, pp. 23—110.
- Ogawa K., Imaida K., Masui T., Kawabe M., Hasegawa R., Kato K., Ito N., Shirai T. (1996). Chemically induced lung and forestomach neoplasias in transgenic mice carry mutant forms of human c-Ha-ras transgene. Carcinogenesis 17:341—345.[Abstract/Free Full Text]
- Ohnishi Y., Arai T., Koshirakawa M., Horii N., Nakajo S., Ueyama Y., Urano K., Usui T., Nomura T. (2001). Induction of drug metabolism-related enzymes by methylcholanthrene and phenobarbital in transgeneic mice carrying human prototype c-Ha-ras gene and their wild type littermates. Exp Anim 50: 33— 39.[Medline]
[Order article via Infotrieve]
- Saitoh A., Kimura M., Takahashi R., Yokoyama M., Nomura T., Izawa M., Sekiya T., Nishimura S., Katsuki M. (1990). Most tumors in transgenic mice with human c-Ha-ras gene contained somatically activated transgenes. Oncogene 5: 1195—1200.[Web of Science][Medline]
[Order article via Infotrieve]
- Sekiya T., Prassolov VS, Fushimi M., Nishimura S. (1985). Transforming activity of the c-Ha-ras oncogene having two point mutations in the codon 12 and 61. Jpn J Cancer Res 76: 851—855.[Web of Science]
- Suemizu H., Ohnishi Y., Maruyama C., Tomisawa M., Muguruma K., Hioki K., Usui T., Kimura M., Tamaoki N., Nomura T. (2001). Molecular biological studies in the rasH2 transgenic mouse. Toxicol Pathol 29(suppl.): xx—xx.
- Tsunematsu S., Saito H., Kagawa T., Morizane T., Hata J., Nakamura T., Ishii H., Tsuchida M., Nomura T., Katsuki M. (1994). Hepatic tumors induced by carbon tetrachloride in transgenic mice carrying a human c-Ha-ras proto-oncogene without mutations. Int J Cancer 15: 554—559.
- Usui T. ( 2001). Neonatal mouse madel: Overview of available data. (this volume).
- Vojtek AB, Der CJ (1998). Increasing complexity of the ras signaling pathway. J Biol Chem 273: 19925—19928.[Free Full Text]
- Yamamoto S., Urano K., Koizumi H., Wakana S., Hioki K., Mitsumori K., Kurokawa Y., Hayashi Y., Nomura T. (1998). Validation of transgenic mice carrying the human prototype c-Ha-ras gene as a bioassay model for rapid carcinogenicity testing. Eniviron Health Perspect 106(Suppl. 1): 57—69.[CrossRef]
Toxicologic Pathology, Vol. 29, No. 1 suppl,
81-89 (2001)
DOI: 10.1080/019262301753178492
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
M. Kawai, M. Jin, J. Nishimura, Y. Dewa, Y. Saegusa, S. Matsumoto, E. Taniai, M. Shibutani, and K. Mitsumori
Hepatocarcinogenic Susceptibility of Fenofibrate and Its Possible Mechanism of Carcinogenicity in a Two-Stage Hepatocarcinogenesis Model of rasH2 Mice
Toxicol Pathol,
December 1, 2008;
36(7):
950 - 957.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Miyamoto, Y. Yasui, M. Kim, S. Sugie, A. Murakami, R. Ishigamori-Suzuki, and T. Tanaka
A novel rasH2 mouse carcinogenesis model that is highly susceptible to 4-NQO-induced tongue and esophageal carcinogenesis is useful for preclinical chemoprevention studies
Carcinogenesis,
February 1, 2008;
29(2):
418 - 426.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. C. L. Schuh
Medical Device Regulations and Testing for Toxicologic Pathologists
Toxicol Pathol,
January 1, 2008;
36(1):
63 - 69.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Okamura, M. Moto, M. Muguruma, T. Ito, M. Jin, Y. Kashida, and K. Mitsumori
A 26-Week Carcinogenicity Study of 2-Amino-3-Methylimidazo[4,5-f]Quinoline in rasH2 Mice
Toxicol Pathol,
February 1, 2006;
34(2):
199 - 205.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Santostefano, D. J. Hoivik, and R. T. Miller
Investigations of Clofibrate in Alternative Carcinogenicity Models
International Journal of Toxicology,
September 1, 2005;
24(5):
285 - 288.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. R. Nesfield, C. J. Clarke, D. J. Hoivik, R. T. Miller, J. S. Allen, K. Selinger, and M. J. Santostefano
Evaluation of the Carcinogenic Potential of Clofibrate in the rasH2 Mouse
International Journal of Toxicology,
September 1, 2005;
24(5):
301 - 311.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. E. Torrey, H. G. Wall, J. A. Campbell, P. Kwanyuen, D. J. Hoivik, R. T. Miller, J. S. Allen, M. J. Jayo, K. Selinger, P. M. Savina, et al.
Evaluation of the Carcinogenic Potential of Clofibrate in FVB/Tg.AC Mouse After Oral Administration--Part I
International Journal of Toxicology,
September 1, 2005;
24(5):
313 - 325.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. E. Torrey, H. G. Wall, J. A. Campbell, P. Kwanyuen, D. J. Hoivik, R. T. Miller, J. S. Allen, M. J. Jayo, K. Selinger, and M. J. Santostefano
Evaluation of the Carcinogenic Potential of Clofibrate in the FVB/Tg.AC Mouse After Dermal Application--Part II
International Journal of Toxicology,
September 1, 2005;
24(5):
327 - 339.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Morton, R. S. Sellers, S. M. Furst, K. D. Hawley, and J. R. May
Effect of Oral Gavage Dosing Regimens in Female Tg rasH2 Transgenic Mice
Toxicol Pathol,
June 1, 2004;
32(4):
413 - 417.
[Abstract]
[PDF]
|
|
|
|
|
|
|
D. L. McCormick and R. Kavet
Animal Models for the Study of Childhood Leukemia: Considerations for Model Identification and Optimization to Identify Potential Risk Factors
International Journal of Toxicology,
May 1, 2004;
23(3):
149 - 161.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Toyosawa, K. Tanaka, T. Imai, K. Yasuhara, T. Koujitani, M. Hirose, and K. Mitsumori
Mutation and Overexpression of the Transgene in Ethylnitrosourea-Induced Tumors in Mice Carrying a Human Prototype c-Ha-ras Gene
Toxicol Pathol,
August 1, 2003;
31(5):
491 - 495.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. R. Payne and C. J. Kemp
p27 Kip1 (Cdkn1b)-Deficient Mice Are Susceptible to Chemical Carcinogenesis and May Be a Useful Model for Carcinogen Screening
Toxicol Pathol,
June 1, 2003;
31(4):
355 - 363.
[Abstract]
[PDF]
|
|
|
|
|
|
|
Committee on Carcinogenicity of Chemicals in Food, Consumer Products and the Environment Statement on ILSI/HESI Research Programme on Alternative Cancer Models
Toxicol Pathol,
February 1, 2003;
31(2):
254 - 257.
[PDF]
|
|
|
|
|
